CStone Pharmaceuticals CEO, President of R&D and Executive Director Acquires 1.0% More Stock

Simply Wall St.

Jun 07

Potential CStone Pharmaceuticals (HKG:2616) shareholders may wish to note that the CEO, President of R&D and Executive Director, Jianxin Yang, recently bought HK$951k worth of stock, paying HK$4.75 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2641173516"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2641173516\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2641173516?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-07 09:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641173516","market":"sg","top_or_hot":-1,"title":"CStone Pharmaceuticals CEO, President of R&D and Executive Director Acquires 1.0% More Stock","media":"Simply Wall St.","content":"<div>\n<p>Potential CStone Pharmaceuticals (HKG:2616) shareholders may wish to note that the CEO, President of R&D and Executive Director, Jianxin Yang, recently bought HK$951k worth of stock, paying HK$4.75 ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-ceo-president-of-rd-and-executive-dir\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CStone Pharmaceuticals CEO, President of R&D and Executive Director Acquires 1.0% More Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCStone Pharmaceuticals CEO, President of R&D and Executive Director Acquires 1.0% More Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-07 09:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-ceo-president-of-rd-and-executive-dir><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Potential CStone Pharmaceuticals (HKG:2616) shareholders may wish to note that the CEO, President of R&D and Executive Director, Jianxin Yang, recently bought HK$951k worth of stock, paying HK$4.75 ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-ceo-president-of-rd-and-executive-dir\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02616","symbol_name":"基石药业-B","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-ceo-president-of-rd-and-executive-dir","article_id":"2641173516","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-ceo-president-of-rd-and-executive-dir","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2641173516","pubTimestamp":1780796541,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Potential CStone Pharmaceuticals ( HKG:2616 ) shareholders may wish to note that the CEO, President of R&D and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"02616":"基石药业-B","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"基石药业首席执行官、研发总裁兼执行董事增持1.0%股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":1},"content_text":"Potential CStone Pharmaceuticals (HKG:2616) shareholders may wish to note that the CEO, President of R&D and Executive Director, Jianxin Yang, recently bought HK$951k worth of stock, paying HK$4.75 for each share.    While that's a very decent purchase to our minds, it was proportionally a bit modest, boosting their holding by just 1.0%.     AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.Advertisement CStone Pharmaceuticals Insider Transactions Over The Last Year   The Non Executive Director, Kenneth Walton Hitchner, made the biggest insider sale in the last 12 months. That single transaction was for HK$6.4m worth of shares at a price of HK$12.75 each.   While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price.  It's of some comfort that this sale was conducted at a price well above the current share price, which is HK$4.70.  So it may not tell us anything about how insiders feel about the current share price.     Happily, we note that in the last year insiders paid HK$19m for 3.14m shares.  On the other hand they divested 994.19k shares, for HK$12m.     Overall, CStone Pharmaceuticals insiders were net buyers during the last year.    You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below.  By clicking on the graph below, you can see the precise details of each insider transaction!  View our latest analysis for CStone Pharmaceuticals SEHK:2616 Insider Trading Volume June 7th 2026 There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).   Insider Ownership Of CStone Pharmaceuticals  I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders.  We usually like to see fairly high levels of insider ownership.   Insiders own 1.6% of CStone Pharmaceuticals shares, worth about HK$117m.  We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.   So What Does This Data Suggest About CStone Pharmaceuticals Insiders?  It is good to see the recent insider purchase.    We also take confidence from the longer term picture of insider transactions.   But on the other hand, the company made a loss during the last year, which makes us a little cautious.     Along with the high insider ownership, this analysis suggests that insiders are quite bullish about CStone Pharmaceuticals.  That's what I like to see!      While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision.     While conducting our analysis, we found that CStone Pharmaceuticals has 2 warning signs and it would be unwise to ignore them.   Of course CStone Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of high quality companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}